ImmunoPrecise Antibodies Ltd. (HYFT) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of ImmunoPrecise Antibodies Ltd. stock $0.69, price $0.94, that is 26.4% below the price, quality 42 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
ImmunoPrecise Antibodies Ltd.
HYFT · USExpensive (fair value 26% below the price), weak company and falling price: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.
How to read this chart
60‑month range $0.3290 – $7.59 · fair‑value band $0.5174 – $0.8624 · the $0.9378 price screens above the $0.6899 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 17, 2026.
Every Wednesday you see whether ImmunoPrecise Antibodies is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
MindWalk Holdings Corp. operates as a bio-native AI company. It focuses on the integration of artificial intelligence, multi-omics data, and advanced laboratory research to accelerate the discovery and development of biologics.
Show moreShow less
The company, through its LensAI platform and HYFT technology, it partners with pharmaceutical and biotechnology companies to drive de-risk drug development and unlock therapeutic possibilities.
The company was formerly known as ImmunoPrecise Antibodies Ltd. and changed its name to MindWalk Holdings Corp. in September 2025. The company was incorporated in 1983 and is headquartered in Austin, Texas.
Stock analysis
ImmunoPrecise Antibodies Ltd. (HYFT) currently trades at $0.9378, while our estimate is $0.6899, 26% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: $0.5174 (bear) to $0.8624 (bull), the price of $0.9378 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
ImmunoPrecise Antibodies Ltd. reported revenue of C$15.3M in FY2026 versus C$19.4M in FY2022, a compound −5.7%/yr. Reported net income was −C$13.7M in FY2026.
Key figures
Market cap $44.6M Micro · P/S ratio 3.31 · EPS (TTM) $−0.2600 · Net margin −89.7% · Return on equity −124% · Return on assets (EBIT) −34.0% (5-year average) · Operating margin −160% · Revenue (TTM) C$16.2M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).
What moves the price
The share trades about 66% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −26%, HYFT screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Compare ImmunoPrecise Antibodies Ltd. with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 848 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Information Technology sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- PEG ratio by industry
- Revenue growth by industry
- PEG screener for stocks with fair value
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $952.40 | $1,275 | +34% | vs HYFT |
| Vertex Pharmaceuticals Incorporated VRTX | $537.79 | $592.46 | +10% | vs HYFT |
| Samsung Biologics Co 207940 | 1,423,000 KRW | 1,552,100 KRW | +9% | vs HYFT |
| argenx SE ARGX | $950.95 | $908.40 | −4% | vs HYFT |
| CSL Limited CSL | A$199.55 | A$186.49 | −7% | vs HYFT |
| Moderna, Inc MRNA | $215.27 | $135.64 | −37% | vs HYFT |
| BeOne Medicines AG 6160 | HK$249.40 | HK$152.92 | −39% | vs HYFT |
| Revolution Medicines, Inc RVMD | $166.87 | $88.78 | −47% | vs HYFT |
| Celltrion, Inc 068270 | 214,500 KRW | 74,945 KRW | −65% | vs HYFT |
| Royalty Pharma plc RPRX | $68.53 | $19.01 | −72% | vs HYFT |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is ImmunoPrecise Antibodies Ltd. (HYFT) overvalued or undervalued?
What is the fair value of HYFT?
What is the quality score of HYFT?
What is the price target for ImmunoPrecise Antibodies Ltd. (HYFT)?
What is the ImmunoPrecise Antibodies Ltd. stock forecast for 2026?
What is the revenue of ImmunoPrecise Antibodies Ltd. (HYFT)?
What is the intrinsic value of ImmunoPrecise Antibodies Ltd. (HYFT)?
Is ImmunoPrecise Antibodies Ltd. stock overvalued or undervalued in 2026?
Is fair value the same as the market price of HYFT?
How much is ImmunoPrecise Antibodies Ltd. worth?
What do the bullish and bearish scenarios say about HYFT?
How solid is the balance sheet of ImmunoPrecise Antibodies Ltd. (HYFT)?
How far is HYFT from its 52-week high?
Which stocks are comparable to ImmunoPrecise Antibodies Ltd.?
Is ImmunoPrecise Antibodies Ltd. stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of ImmunoPrecise Antibodies Ltd. (HYFT)?
What should I pay attention to with ImmunoPrecise Antibodies Ltd. right now?
Key figures of ImmunoPrecise Antibodies Ltd.
How large is the market capitalisation of ImmunoPrecise Antibodies Ltd. (HYFT)?
What is the P/S ratio of ImmunoPrecise Antibodies Ltd. (HYFT)?
What are the earnings per share of ImmunoPrecise Antibodies Ltd. (HYFT)?
What is the net margin of ImmunoPrecise Antibodies Ltd. (HYFT)?
What is the return on equity of ImmunoPrecise Antibodies Ltd. (HYFT)?
What is the EBIT return on assets of ImmunoPrecise Antibodies Ltd. (HYFT)?
What is the operating margin of ImmunoPrecise Antibodies Ltd. (HYFT)?
How fast is revenue growing at ImmunoPrecise Antibodies Ltd. (HYFT)?
How much free cash flow does ImmunoPrecise Antibodies Ltd. (HYFT) generate?
How much net cash does ImmunoPrecise Antibodies Ltd. (HYFT) hold?
Watch ImmunoPrecise Antibodies Ltd. in the live analysis
One click puts ImmunoPrecise Antibodies Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.